MedTrace Logo

Noradrenalin vs Terlipressin in Hepatorenal Syndrome

NCT00370253 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-04-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome

Conditions

  • Hepatorenal Syndrome

Interventions

DRUG

Terlipressin

1mg/4 h per day

DRUG

Noradrenalin

0,1 mcg/kg/min

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Principal Investigators

  • Mario Rizzetto, MD · Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, Turin, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370253 on ClinicalTrials.gov